Literature DB >> 18007145

Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods.

Cria O Gregory1, Chunli Yu, Rani H Singh.   

Abstract

PURPOSE: Blood phenylalanine monitoring is critical for the management of phenylketonuria. We compared three methods for measuring blood phenylalanine concentration: the amino acid analyzer, high-performance liquid chromatography with fluorometric detection, and tandem mass spectrometry.
METHODS: We studied 22 female patients with phenylketonuria, ages 12-48 years, who attended our Metabolic Camp. Blood was collected into heparinized tubes (for analysis by the amino acid analyzer) or filter paper (for analysis by high-performance liquid chromatography with fluorometric detection and tandem mass spectrometry).
RESULTS: Blood phenylalanine concentrations of plasma measured by the amino acid analyzer were significantly higher than those obtained from whole blood on filter paper by high-performance liquid chromatography (difference: 102 microM; 95% confidence interval: 23, 181) and tandem mass spectrometry (difference: 137 microM; 95% confidence interval: 58, 216). Phenylalanine concentrations from high-performance liquid chromatography and tandem mass spectrometry were not significantly different (P = 0.5).
CONCLUSIONS: When monitoring blood phenylalanine concentrations for dietary compliance, clinicians should be mindful of the method being used; analyses of whole blood on filter paper were consistently approximately 15% lower than analyses of plasma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007145     DOI: 10.1097/GIM.0b013e318159a355

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  17 in total

1.  A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study.

Authors:  S H L Yi; J A Kable; M L Evatt; R H Singh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-10-14       Impact factor: 4.006

2.  Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria.

Authors:  Rani H Singh; Meghan E Quirk
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

3.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

4.  What Is the Best Blood Sampling Time for Metabolic Control of Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients?

Authors:  Esther van Dam; Anne Daly; Gineke Venema-Liefaard; Margreet van Rijn; Terry G J Derks; Patrick J McKiernan; M Rebecca Heiner-Fokkema; Anita MacDonald; Francjan J van Spronsen
Journal:  JIMD Rep       Date:  2017-01-25

5.  Predictive equations underestimate resting energy expenditure in female adolescents with phenylketonuria.

Authors:  Meghan E Quirk; Brian J Schmotzer; Rani H Singh
Journal:  J Am Diet Assoc       Date:  2010-06

Review 6.  Nutritional management of PKU with glycomacropeptide from cheese whey.

Authors:  D M Ney; S T Gleason; S C van Calcar; E L MacLeod; K L Nelson; M R Etzel; G M Rice; J A Wolff
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

7.  Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.

Authors:  Nicola Longo; Cary O Harding; Barbara K Burton; Dorothy K Grange; Jerry Vockley; Melissa Wasserstein; Gregory M Rice; Alejandro Dorenbaum; Jutta K Neuenburg; Donald G Musson; Zhonghua Gu; Saba Sile
Journal:  Lancet       Date:  2014-04-14       Impact factor: 79.321

8.  Cardiac teratogenicity in mouse maternal phenylketonuria: defining phenotype parameters and genetic background influences.

Authors:  Nikki J Seagraves; Kim L McBride
Journal:  Mol Genet Metab       Date:  2012-08-08       Impact factor: 4.797

Review 9.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

10.  COMPARISON OF PLASMA PHENYLALANINE DETERMINATION BY DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS AND BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY IN RELATION WITH THE SCREENING OF PHENYLKETONURIA.

Authors:  C V Mihali; M C Petrescu; I Mândruţiu; D Bechet; T V Nistor; V Turcuş; A Ardelean; Gh Benga
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Apr-Jun       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.